A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: No treatment is included in this protocol..
- Who it may be relevant to
- Registry conditions: Advanced Lung Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Real-World Treatment Patterns and Effectiveness of Targeted and Systemic Therapy in Patients With Advanced Lung Cancer Carrying MET Mutation-Positive
Overview
This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data will be collected in a forward-looking manner. This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data from patients on prior treatment will be collected retrospectively, and data from patients who will be treated later and included in the study will be collected in a prospective manner. The criteria for retrospective collection were consistent with those for prospective collection. Eligible patients will be enrolled after NGS analysis of tumor tissue and informed consent has been obtained. Information required for the study will be collected (every 3 months).
Interventions
- Other No treatment is included in this protocol.
No drug intervention or tissue sampling will be included in this study.
Primary outcome measures
- Progression-Free-Survival [Time frame: Assessed up to around 4.5 years]
- Overall Survival [Time frame: Assessed up to around 4.5 years]
Secondary outcome measures (3)
- Clinical relevance between genomic profiling and progression-free-survival [Time frame: Assessed up to around 4.5 years]
- Clinical relevance between genomic profiling and overall survival [Time frame: Assessed up to around 4.5 years]
- ORR [Time frame: Assessed up to around 4.5 years]
Eligibility criteria
Inclusion criteria
- Patients must be ≥18 years of age.
- Provision of fully informed consent prior to any study specific procedures.
- Histologically or cytologically confirmed, unresectable stage IIIB/IIIC or stage IV NSCLC.
- Genetic variants of tumor tissue detected by NGS.
Exclusion criteria
None.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Hunan Province Tumor Hospital — Changsha
Identifiers
NCT: NCT06183762 · MET RWS